- Home
- GMAB vs SNN Comparison
GMAB vs SNN Comparison
Compare GMAB & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- SNN
- Stock Information
- Founded
- GMAB 1999
- SNN 1856
- Country
- GMAB Denmark
- SNN United Kingdom
- Employees
- GMAB N/A
- SNN N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- SNN Industrial Specialties
- Sector
- GMAB Health Care
- SNN Health Care
- Exchange
- GMAB Nasdaq
- SNN Nasdaq
- Market Cap
- GMAB 17.4B
- SNN 15.5B
- IPO Year
- GMAB N/A
- SNN 1999
- Fundamental
- Price
- GMAB $29.93
- SNN $36.62
- Analyst Decision
- GMAB Strong Buy
- SNN Hold
- Analyst Count
- GMAB 7
- SNN 4
- Target Price
- GMAB $41.17
- SNN $33.50
- AVG Volume (30 Days)
- GMAB 3.1M
- SNN 644.1K
- Earning Date
- GMAB 11-06-2025
- SNN 10-30-2025
- Dividend Yield
- GMAB N/A
- SNN 2.00%
- EPS Growth
- GMAB 77.72
- SNN 59.91
- EPS
- GMAB 21.62
- SNN 0.56
- Revenue
- GMAB $3,646,881,232.00
- SNN $5,944,000,000.00
- Revenue This Year
- GMAB $24.25
- SNN $7.75
- Revenue Next Year
- GMAB $16.29
- SNN $5.40
- P/E Ratio
- GMAB $13.36
- SNN $31.69
- Revenue Growth
- GMAB 32.97
- SNN 5.35
- 52 Week Low
- GMAB $17.24
- SNN $23.69
- 52 Week High
- GMAB $33.65
- SNN $38.79
- Technical
- Relative Strength Index (RSI)
- GMAB 46.39
- SNN 54.98
- Support Level
- GMAB $29.57
- SNN $34.69
- Resistance Level
- GMAB $30.24
- SNN $37.51
- Average True Range (ATR)
- GMAB 0.67
- SNN 0.45
- MACD
- GMAB -0.58
- SNN 0.14
- Stochastic Oscillator
- GMAB 11.11
- SNN 68.44
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.